BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 28, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

VX-770: Phase II data

The double-blind, U.S. Phase II DISCOVER trial in 140 patients with 2 copies of the delta F508 CFTR mutation showed that twice-daily 150 mg oral VX-770 missed the co-primary endpoint of significantly improving the mean absolute change in FEV1 from baseline to week 16 vs. placebo. Specifically, the mean absolute improvement in FEV1 at week 16...

Read the full 256 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >